6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma

September 26-29, 2018
Rotterdam, The Netherlands
Venue: De Doelen International Congress Centre

Pre-Symposium Workshop
Sept 26, 2018

Presenting the latest scientific and clinical advances in childhood, adolescent and young adult Non-Hodgkin Lymphoma

Hosted By:
Mitchell S. Cairo, MD - Chair
Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation
Professor of Pediatrics, Medicine, Pathology, Microbiology & Immunology and Cell Biology & Anatomy
Maria Fareri Children’s Hospital
Westchester Medical Center (WMC)
New York Medical College

Auke Beishuizen, MD, PhD, - Co-Chair
Pediatric Oncologist/Hematologist
Erasmus MC – Sophia Children’s Hospital
University Medical Center Rotterdam
And
Princess Máxima Center for Pediatric Oncology
Utrecht

For more information please go to http://cayanhl.pcrf-kids.org
or http://www.cayanhl2018.com

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of New York Medical College and Pediatric Cancer Research Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this Live activity for a maximum of 23.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
**SCHEDULE AT A GLANCE**

<table>
<thead>
<tr>
<th>Wednesday September 26th</th>
<th>Thursday September 27th</th>
<th>Friday September 28th</th>
<th>Saturday September 29th</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Registration</strong> 2:00 PM – 9:00 PM</td>
<td><strong>Registration</strong> 7:00 AM – 5:00 PM</td>
<td><strong>Registration</strong> 7:00 AM – 5:00 PM</td>
<td><strong>Registration</strong> 7:00 AM – 1:00 PM</td>
</tr>
<tr>
<td><strong>NHL Wellness and Survivorship</strong> 6:00 PM – 8:00 PM</td>
<td><strong>Opening Ceremony</strong> 8:00 AM – 8:15 AM</td>
<td><strong>Meet the Professors</strong> 7:30 AM – 8:15 AM</td>
<td><strong>Meet the Professors</strong> 7:30 AM – 8:15 AM</td>
</tr>
<tr>
<td><strong>Plenary Session I</strong> B-Cell NHL 9:00 AM – 10:45 AM</td>
<td><strong>Plenary Session V</strong> Anaplastic Large Cell Lymphoma 8:30 AM – 10:15 AM</td>
<td><strong>Plenary Session IX</strong> Best Oral Abstracts in Childhood, Adolescent and Young Adult NHL 8:30 AM – 10:00 AM</td>
<td></td>
</tr>
<tr>
<td><strong>Break</strong> 10:45 AM – 11:00 AM</td>
<td><strong>Break</strong> 10:15 AM – 10:30 AM</td>
<td><strong>Break</strong> 10:00 AM – 10:15 AM</td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session II</strong> Adolescent and Young Adult NHL &amp; HL 11:00 AM – 12:40 PM</td>
<td>**Plenary Session VI T and NK NHL 10:30 AM – 12:15 PM</td>
<td><strong>Plenary Session X</strong> Lymphoblastic Lymphoma 10:15 – 11:45 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Lunch</strong> 12:45 – 1:45 PM</td>
<td><strong>Lunch</strong> 12:15 – 1:45 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session III</strong> Lymphoma Translational Biology (Dedicated in memory of Warren Sanger, PhD) 1:45 PM – 3:45 PM</td>
<td><strong>Plenary Session VII</strong> Novel Therapeutics 1:15 PM – 1:30 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Break</strong> 3:45 PM – 4:00 PM</td>
<td></td>
<td><strong>Plenary Session VIII</strong> Poster Discussion 3:00 PM – 6:00 PM</td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session IV</strong> Lymphoma Immunology, BMT and Cell Therapy 4:00 PM – 5:45 PM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Welcome Reception</strong> 6:00 PM – 7:30 PM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Chair:** Mitchell S. Cairo, MD, USA  
**Co-Chair:** Auke Beishuizen, MD, PhD, Netherlands  

**International Scientific Committee & Faculty:**  
Oussama Abla, MD, Canada  
Sarah Alexander, MD, Canada  
Carl Allen, MD, PhD, USA  
Mara Andres, MD, PhD, Spain  
Stephen M. Ansell, MD, PhD, USA  
Andishe Attarbaschi, MD, Austria  
Anthony N. Audino, MD  
Matthew Barth, MD, USA  
Myriam Weyl Ben, MD  
Michelle Hermiston, MD, PhD, USA  
Jan Loeffen, MD, USA  
Joseph Lubega, MD, Uganda  
Ryoko Kobayashi, MD, PhD, Japan  
Yukhi Koga, MD, PhD, Japan  
M. Tezer Kutlu, MD, PhD, Turkey  
Megan Lim, MD, PhD, USA  
Michael Link, MD, USA  
Jan Loeffen, MD, PhD, Netherlands  
Eric Lowe, MD, USA  
Joseph Lubega, MD, MPH, Uganda  
Elizabeth Macintyre, MD, PhD, France  
Britta Maeker-Kolhoff, MD, Germany  
Christine Mauz-Körholz, MD, Germany  
Linda McAllister-Lucas, MD, PhD, USA  
Monika Metzger, MD, MSc, USA  
Friederike Meyer-Wentrup, MD, Netherlands  
Rodney Miles, MD, PhD, USA  
Veronique Minard-Colin, MD, PhD, France  
Tetsuya Mori, MD, PhD, Japan  
Lara Mussolin, PhD, Italy  
Ryotaro Nakamura, MD, USA  
Laura Pasqualucci, MD, USA  

**International Scientific Committee & Faculty: (Continued)**  
Catherine Patte, MD, France  
Sherrie Perkins, MD, PhD, USA  
Rob Pieters, MD, Netherlands  
Marta Pillow, MD, Italy  
Leticia Quintanilla-Fend, MD, Germany  
Alfred Reiter, MD, Germany  
Stanley Riddell, MD, USA  
Leslie Robison, PhD, USA  
Lisa Giulino-Roth, MD, USA  
Elena V. Samochatova, MD, PhD, Russia  
John T. Sandlund, MD, USA  
Jennifer Sanmann, PhD, USA  
Florian Scherer, MD, Germany  
Margaret Shipp, MD, USA  
Bruce Shiramizu, MD, USA  
Reiner Siebert, MD, Germany  
Filippo Spreafico, MD, Italy  
Jaroslav Sterba MD, PhD, Czech Republic  
Jan Styczynski, MD, Poland  
X. F. Sun, MD, China  
Ritsuro Suzuki, MD, Japan  
Suzanne Turnier, PhD, UK  
Anne Uyttebroeck, MD, PhD, Belgium  
Timur T.Valiev, MD, PhD, Russia  
Rein Willemsen, MD, Netherlands  
Birte Wistinghausen, MD, USA  
Wilhelm Woessmann, MD, Germany  
Ana Xavier, MD, USA  
Jing Yang, MD, China  
Yonghong Zhang, MD, China  
Josef Zsirós, MD, Netherlands  
Christian Michel Zwaan, MD, PhD, Netherlands
Wednesday, September 26, 2018

2:00 – 9:00 PM
REGISTRATION

6:00 – 8:00 PM
Pre-Congress Workshop
Childhood and Adolescent NHL Wellness and Survivorship
Jessica Hochberg, MD, USA & Leslie Robison, PhD, USA

6:00 – 6:30 PM
CHILDHOOD AND ADOLESCENT NHL SURVIVORSHIP: THE CCSS PERSPECTIVE
Leslie Robison, PhD, USA

6:30 – 6:45 PM
CHILDHOOD AND ADOLESCENT NHL SURVIVORSHIP: THE BFM PERSPECTIVE
Birgit Burkhardt, MD, PhD, Germany & Wilhelm Woessmann, MD, Germany

6:45 – 7:00 PM
Burkitt Lymphoma (BL): Effect of Cyclophosphamide (CPM) on the Menarche and Fertility Rate in 113 Cameroonian patients.
Peter B Hesseling¹, Glenn Afunchwi², Vera Njamshi³, Comfort Kimbi⁴, Patience Nfor⁵, Bernard Njodzeka⁶, Paul Wharin⁷, Francine Kouya⁸, Heather R Draper ⁹
¹Department of Paediatrics and Child Health, Tygerberg Children’s Hospital, University of Stellenbosch, South Africa, ²Banso Baptist Hospital, Northwest Region, Cameroon, ³Banso Baptist Hospital, Northwest Region, Cameroon, ⁴Mbingo Baptist Hospital, Northwest region, Cameroon, ⁵Mutengene Baptist Hospital, Southwest Region, Cameroon, ⁶Mutengene Baptist Hospital, Southwest Region, Cameroon, ⁷Beryl Thyer Memorial Africa Trust, Kettering, UK, ⁸Mbingo Baptist Hospital, Northwest Region, Cameroon; Heather R Draper MSc — ⁹Desmond Tutu TB Centre, Department of Paediatrics, University of Stellenbosch, South Africa

7:00 – 7:15 PM
Influence of Methylene tetrahydrofolate Reductase Gene Polymorphisms on the High-dose Methotrexate Related Toxicity in Children Cancer Patients
Suying Lu, MD¹,²,³, Xiaofei Sun, MD¹,²,³*, Zijun Zhen, MD, PhD¹,²,³, Jia Zhu, MD, PhD¹,²,³, Juan Wang, MD¹,²,³, Feifei Sun, MD, PhD¹,²,³, Junting Huang, MD, PhD¹,²,³.
¹State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China; ²Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China; ³Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China

7:15 – 7:30 PM
Long Term Follow Up of Pediatric Lymphoma Survivors upon Entry into a Wellness and Survivorship Program
Jessica Hochberg, MD¹; Tara Giblin, PNP¹; Suzanne Braniecki, PhD¹, Rose Bartone, LCSW¹, Lauren Harrison, RN, MSN¹, Jackie Basso, RN, MSN, PNP¹, Allyson Flower, MD¹ and Mitchell Cairo, MD¹,²,³,⁴,⁵
¹Pediatrics, New York Medical College, Valhalla, NY; ²Medicine, ³Pathology, ⁴Microbiology and Immunology and ⁵Cell Biology and Anatomy, New York Medical College, Valhalla, NY

7:30 – 8:00 PM
Panel Discussion – Drs. Hochberg, Robison, Burkhardt and Audience Participation
Thursday, September 27, 2018

7:00 AM - 5:00 PM  REGISTRATION

8:00 – 8:10 AM  OPENING CEREMONY
Mitchell S. Cairo, MD, Chair, USA

8:10 – 8:15 AM  Auke Beishuizen, MD, PhD, Co-Chair, Netherlands

8:15 – 9:00 AM  ANGELO ROSOLEN, MD, MEMORIAL LECTURE

8:15 – 8:20 AM  INTRODUCTION
Marta Pillon, MD, Italy, and Lara Mussolin, PhD, Italy - Co-Chairs

8:20 – 9:00 AM  PEDIATRIC NON-HODGKIN LYMPHOMA REVISITED WITH A VIEW FROM THE DISTANCE
Alfred Reiter, MD, Germany

9:00 – 10:45 AM  PLENARY SESSION I - B-CELL NON-HODGKIN LYMPHOMA
Moderators - Stanton Goldman, MD, USA & Sarah Alexander, MD, Canada

9:00 – 9:20 AM  PROMISING TARGETS IN B-CELL PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Margaret Shipp, MD, USA

9:20 – 9:40 AM  DNA METHYLOME IN BURKITT LYMPHOMA
Reiner Siebert, MD, Germany

9:40 – 10:00 AM  DIAGNOSIS AND TREATMENT OF RARE B-NHL VARIANTS IN CHILDREN AND ADOLESCENTS
Andishe Attarbaschi, MD, Austria

10:00 – 10:10 AM  Reduced Burden of Oncologic Therapy in Children, Adolescents and Young Adults with Good Risk (GR) CD20+ Mature B-Cell Lymphoma
Stan Goldman, MD1 Matthew Barth, MD2, Jessica Hochberg, MD3, Liana Klejmont, Pharm D3, Lauren Harrison, RN, MSN3, Quihi Shi, PhD3, Javier Oesterheld, MD4, Kenneth Heym, MD5, Sherrie Perkins, MD, PhD6, Rodney Miles, MD, PhD6, Bruce Shiramizu, MD7, and Mitchell Cairo, MD3,8,9,10,11,12

1Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX; Departments of 2Pediatrics, Roswell Park Cancer Institute, Buffalo, NY; 3Pediatrics, Medicine, 9Pathology, 10Microbiology & Immunology, 11Cell Biology & Anatomy, 12Biostatistics, New York Medical College, Valhalla, NY; 4Levine Children’s Hospital, Charlotte, NC; 5Cook Children's Medical Center, 6Pathology, University of Utah Health, Salt Lake City, UT; 7Tropical Medicine, Medical Microbiology & Pharmacology, University of Hawaii, Honolulu, HI.

10:10 – 10:20 AM  Cancer Stem Cells in Paediatric B-Cell Non-Hodgkin Lymphoma are Detectable by Side Population Analysis and May Contribute to Therapy Resistance
Sorcha Forde1, Nina Prokoph1, Liam C. Lee1, Simon Bomken2, G.A. Amos Burke3*, and Suzanne D. Turner1*
10:20 – 10:30 AM  **UCH-L1 Bypasses mTOR to Promote Protein Biosynthesis and is Required for MYC Driven Lymphomagenesis in Mice**  
Sajjad Hussain\(^1\), Tibor Bedekovic\(^1\), Qiuling Liu\(^2\), Wenqian Hu\(^2\), Sarah H. Johnson\(^3\), George Vasmatzis\(^3, 4\), Danielle G. May\(^5\), Kyle J. Roux\(^5, 6\), and Paul J. Galardy\(^1, 2, 7\)  
\(^1\)Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA; \(^2\)Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, 55905; \(^3\)Center for Individualized Medicine-Biomarker Discover, Mayo Clinic, Rochester, MN, 55905; \(^4\)Department of Molecular Medicine, Mayo Clinic, Rochester, MN, 55905; \(^5\)Enabling Technology Group, Sanford Research, Sioux Falls, SD 57104, USA; \(^6\)Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA; \(^7\)Division of Pediatric Hematology-Oncology, Mayo Clinic, Rochester, MN 55905, USA

10:30 – 10:45 AM  **Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers**

10:45 – 11:00 AM  **COFFEE BREAK**

11:00 – 12:40 PM  **PLENARY SESSION II - ADOLESCENT AND YOUNG ADULT NON-HODGKIN AND HODGKIN LYMPHOMA**  
**Moderators** - Monika Metzger, MD, MSc, USA & Christine Mauz-Körholz, MD, Germany

11:00 – 11:20 AM  **PD-1 TARGETED THERAPY IN LYMPHOMAS**  
Steve Ansell, MD, PhD, USA

11:20 – 11:40 AM  **EPIDEMIOLOGY AND OUTCOME OF AYA WITH NHL AND HODGKIN LYMPHOMA**  
Allyson Flower, MD, USA

11:40 – 12:00 PM  **NOVEL TARGETED IMMUNOTHERAPY IN NEWLY DIAGNOSED CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA**  
Jessica Hochberg, MD, USA

12:00 – 12:10 PM  **Nonbiological Factors Affecting Outcomes in Adolescent and Young Adults with Lymphoma.**  
Ana C. Xavier\(^1\), Luciano J. Costa\(^2\)  
\(^1\)Division of Hematology/Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States; \(^2\)Division of Hematology and Medical Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.

12:10 – 12:20 PM  **Clinical Features and Treatment Outcome of Children with Primary Mediastinal Large B-Cell Lymphoma in Taiwan**  
Shih-Hsiang Chen\(^1\), Chao-Ping Yang\(^3\), on behalf of the Taiwan Pediatric Oncology Group (TPOG)
Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

LUNCH

PLENARY SESSION III - LYMPHOMA TRANSLATIONAL BIOLOGY (DEDICATED IN MEMORY OF WARREN SANGER, PHD)
Moderators - Paul Galardy, MD, USA & Elizabeth Macintyre, MD, PhD, France

INTRODUCTION
Jennifer N. Sanmann, PhD, USA

THE T/MEYOID INTERFACE IN IMMATURE T LYMPHOID MALIGNANCIES"
Elizabeth Macintyre, MD, PhD, France

CIRCULATING TUMOR DNA (CTDNA) IN B-CELL LYMPHOMA
Florian Scherer, MD, USA

THE ROLE OF LIQUID BIOPSY IN NON-HODGKIN LYMPHOMAS OF CHILDHOOD
Lara Mussolin, PhD, Italy

MUTATIONAL LANDSCAPE OF PEDIATRIC-TYPE FOLLICULAR LYMPHOMA
Leticia Quintanilla-Fend, MD, Germany

Discovery of the First Zebrafish B Cell Lymphoblastic Lymphoma Model
Chiara Borga PhD, Gilseung Park, Clay Foster PhD, Jessica Burroughs-Garcia PhD, Ameera Hasan MBBS, Rikin Shah MD, Megan Malone-Perez, Teresa Scordino MD, Rodney R. Miles MD, PhD, James L. Regens PhD, Geertruy te Kronnie PhD, J. Kimble Frazer MD, PhD

IG-MYC-Positive Leukemia and Lymphoma with Precursor B-Cell Phenotype are Genetically and Epigenetically Distinct from Burkitt Lymphomas
3:25 – 3:35 PM  Mutational Spectrum of Relapse in Pediatric and Adolescent Patients with T-LBL
Tasneem Khanam, Charlotte Rüther, Christoph Bartenhagen, Jochen Seggewiß, Heidi Herbrüggen, Stephanie Müller, Christian Wünsch, Ilske Oschlies, Wolfram Klapper, Martin Dugas, Sarah Sandmann, Birgit Burkhardt
1Paediatric Hematology and Oncology, University Hospital Muenster, Germany, 2Institute of Medical Informatics, Muenster University, 3Institute of Human genetics, Muenster University, 4Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany, 5Department of Experimental Pediatric Oncology, University of Cologne

3:35 – 3:50PM  Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

3:50 – 4:00 PM  COFFEE BREAK

4:00 – 5:45 PM  PLENARY SESSION IV - LYMPHOMA IMMUNOLOGY, BMT AND CELL THERAPY
Moderators – Wilhelm Woessmann, MD, Germany & Mitchell S. Cairo, MD, USA
4:00 – 4:20 PM  HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY NHL
Wilhelm Woessmann, MD, Germany

4:20 – 4:40 PM  NEW ADVANCES ON CAR-T-CELL THERAPY IN B-NHL
Stanley Riddell, MD, USA

4:40 – 5:00 PM  CMV-CD19 BI-SPECIFIC CAR T CELLS AND POST-INFUSION CMV VACCINE STRATEGIES
Ryotaro Nakamura, MD, USA

5:00 – 5:10 PM  Safety and Efficacy of Myeloablative Conditioning Autologous Stem Cell Transplantation, Targeted Immunotherapy, and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Children, Adolescents, and Young Adults with Relapsed/Refractory Mature B-Cell Non Hodgkin Lymphoma
A Gardenswartz, MD1, B Mehta, MD1, N El-Mallawany, MD1, C van de Ven, MS1, J Hochberg, MD1, A Flower, MD1, E Morris, RN, BSN1, L Harrison, RN, MSN1, J Basso, RN, MSN, CPNP1, P Gerard2, J Ayello, MS1, L A Baxter-Lowe, PhD3, M S Cairo, MD1,4,5,6,7.
1 Dept of Pediatrics, New York Medical College, Valhalla, NY; 2 Dept of Radiology, New York Medical College, Valhalla, NY; 3 Dept of Pathology, Children’s Hospital Los Angeles, CA; 4 Dept of Medicine, New York Medical College, Valhalla, NY; 5 Dept of Pathology, New York Medical College, Valhalla, NY; 6 Dept of Microbiology and Immunology, and 7 Dept of Cell Biology and Anatomy, New York Medical College, Valhalla, NY

5:10 – 5:20 PM  Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells
Julie Rivers1, Colleen Annesley1, Corinne Summers1, Olivia Finney2, Michael Pulsipher3, Alan Wayne3, Julie Park1, Michael Jensen3, Rebecca Gardner1
1 Seattle Children’s Hospital, Seattle, WA, USA; 2 Seattle Children’s Research Institute, Seattle, WA, USA; 3 Children’s Hospital of Los Angeles, Los Angeles, CA, USA

5:20 – 5:30 PM  Role of HSCT in Children and Adolescents with Refractory or Relapsed NHL
Birgit Burkhardt1, Marta Pillon2, Mary Taj3, Nathalie Garnier4, Veronique Minard5, Volkan Hazar6, Karin Mellgren7, Tomoo Osumi8, Alina Fedorova9, Natalia Myakova10, Jaime Verdu-Amoros11, Mara Andres12, Edita Kabickova13, Andishe Attarbaschi14, Alan Chiang15, Eva Bubanska16, Svetlana Donska17, Lisa Lyngsie Hjalgrim18, Jacek Wachowiak19, Anna Pieczonka19, Anne Uytttebroeck20, Jan Loeffen21, Jochen Buechner22, Felix Niggli23, Julia Palma24, Amos Burke25, Auke Beishuizen21, Kristin Koeppen1, Heidi Herbreuggen1, Wilhelm Woessmann26, Martin Zimmermann27, Adriana Balduzzi28
1 University Hospital Muenster, Department of Pediatric Hematology, Oncology and BMT, Muenster, Germany; 2 University-Hospital of Padua, Department of Child and Woman Health, Oncology Hematology Division, Padua, Italy; 3 Royal Marsden Hospital, Department of Paediatric Oncology, Surrey, United Kingdom; 4 Hospices Civils de Lyon, Institute of Pediatric Hematology and Oncology, Lyon cedex, France; 5 Gustave Roussy Cancer Campus, Department of Pediatric Oncology, Villejuif, France; 6 Medical Park Goztepe Hospital, Departments of Pediatric Hematology and Oncology and BMT Unit, Istanbul, Turkey; 7 Sahlgrenska University Hospital, Department of Pediatric Oncology and Hematology, The Queen Silvia Children’s Hospital, Gothenburg, Sweden; 8 Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan; 9 Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Clinical Research Department, Minsk, Belarus; 10 Pediatric Hematology and Oncology, Children’s Hospital of Los Angeles, Los Angeles, CA, USA
Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, University Hospital Valencia, Department of Pediatric Hematology and Oncology, Valencia, Spain, University Hospital Le Fe, Department of Pediatric Oncology, Valencia, Spain, Charles University & University Hospital Motol, Department of Paediatric Haematology and Oncology, Prague, Czech Republic, St. Anna Children's Hospital, Medical University of Vienna, Department of Pediatric Hematology and Oncology, Vienna, Austria, Department of Pediatrics & Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Slovak Health University and Children's Faculty Hospital, Clinic of Pediatric Oncology and Hematology, Banská Bystrica, Slovakia, National Ukrainian Children’s Hospital “Ochmatdyt”, Center of Pediatric Oncohematology and BMT, Kiev, Ukraine, Department of Paediatrics and Adolescent Medicine, Copenhagen, Denmark, Poznan University of Medical Sciences, Department of Pediatric Oncology, Hematology and Transplantology, Poznan, Poland, University Hospital Gasthuisberg, Department of Paediatric Haematology and Oncology, Leuven, Belgium, Erasmus Medical Center Rotterdam, Sophia Children’s Hospital, Department of Pediatric Oncology and Hematology, Rotterdam, The Netherlands, Oslo University Hospital, Department of Pediatric Hematology and Oncology, Oslo, Norway, University Children’s Hospital Zurich, Department of Pediatric Oncology, Zürich, Switzerland, University of Chile – Faculty of Medicine, Hospital Luis Calvo Mackenna, Department of Pediatrics – Bone Marrow Transplantation Unit, Santiago, Chile, Cambridge University Hospitals NHS Foundation Trust, Department of Paediatric Haematology and Oncology and Palliative Care, Addenbrooke’s Hospital, Cambridge, United Kingdom, Justus-Liebig-University, Department of Pediatric Hematology and Oncology, Giessen, Germany, Hannover Medical School, Department of Pediatric Hematology and Oncology, Hannover, Germany, Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy

5:30 – 5:45 PM  Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

6:00 – 7:30 PM  WELCOME RECEPTION (ALL REGISTRANTS/FACULTY/STAFF/SIGNIFICANT OTHERS)

LOCATION: ROTTERDAM CITY HALL

Friday, September 28, 2018

7:00 AM - 5:00 PM  REGISTRATION

7:30 – 8:30 AM  Meet the Professors (Choose One Session)

Session 1  MOLECULAR GENETICS IN NON-HODGKIN LYMPHOMA FOR THE CLINICIAN
Wolfram Klapper, MD, Germany

Session 2  DIAGNOSIS AND TREATMENT OF MATURE B-CELL LYMPHOMA IN CHILDREN: CHALLENGING CASES
Catherine Patte, MD, France
| Session 3 | NEW PEDIATRIC INTERNATIONAL STAGING AND RESPONSE CRITERIA FOR CHILDHOOD AND ADOLESCENT NHL  
John Sandlund, MD, USA |
| Session 4 | HISTIOCYTOSIS SYNDROMES: NEW DIRECTIONS AND CHALLENGING CASES  
Carl Allen, MD, PhD, USA |
| Session 5 | NEW PATHOLOGICAL ENTITIES IN NHL: THE REVISED WHO CLASSIFICATION  
Sherrie Perkins, MD, PhD, USA |

**8:30 – 10:15 AM**  
**PLENARY SESSION V - ANAPLASTIC LARGE CELL LYMPHOMA**  
**Moderators** - Eric Lowe, MD, USA & Suzanne Turner, PhD, UK

**8:30 – 8:50 AM**  
**PRIMARY CUTANEOUS ALCL AND OTHER CUTANEOUS LYMPHOMAS IN CHILDREN AND ADOLESCENTS**  
Rein Willeme, MD, Netherlands

**8:50 – 9:10 AM**  
**NOVEL PATHWAYS OF ONCOGENESIS IN ALCL**  
Megan Lim, MD, PhD, USA

**9:10 – 9:30 AM**  
**ORIGINS AND PATHOGENESIS IN ALCL**  
Suzanne Turner, PhD, UK

**9:30 – 9:40 AM**  
**Comprehensive Characterization of Plasma-Derived Exosomes in Anaplastic Large Cell Lymphoma of Childhood**  
Federica Lovisa$^{1,2}$, Enrico Gaffo$^1$, Stefania Bortoluzzi$^3$, Anna Garbin$^{1,2}$, Piero Di Battista$^{1,2}$, Elisa Carraro$^1$, Piero Faruggia$^4$, Alessandra Sala$^5$, Matilde Piglione$^6$, Luciana Vinti$^7$, Emanuele S.G. D’Amore$^8$, Giuseppe Basso$^{1,2}$, Marta Pilon$^1$, Lara Mussolin$^{1,2}$  
$^1$Clinic of Paediatric Onco-Haematology, Department of Women’s and Children’s Health, University of Padova, $^2$Istituto di Ricerca Pediatrica Città della Speranza, Padova, $^3$Department of Molecular Medicine, University of Padova, Padova, $^4$A.R.N.A.S. Ospedali Civico Di Cristina e Benfratelli, Palermo, $^5$Department of Paediatrics, San Gerardo Hospital, University of Milano-Bicocca, Fondazione MBBM, Monza, $^6$Department of Paediatric Onco-Haematology, Children’s Hospital Regina Margherita, Torino, $^7$Department of Paediatric Onco-Haematology, IRCCS Ospedale Bambino Gesù, Roma, $^8$Department of Pathological Anatomy, San Bortolo Hospital, Vicenza, Italy

**9:40 – 9:50 AM**  
**Examining the Function of PDGFRB in Anaplastic Large Cell Lymphoma**  
Ines Garces de los Fayos Alonso$^{1,2,3}$, Michael Kothmayer$^{2,3}$, Michaela Schlederer$^2$, Oliver Pusch$^4$, Simone Tangermann$^2$, Sabine Lagger$^3$ and Lukas Kenner$^{1,2,3}$  
$^1$Ludwig Boltzmann Institute for Cancer Research (LBI-CR), 1090 Vienna, $^2$Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, $^3$Unit of Laboratory Animal Pathology, Veterinary University of Vienna, 1210 Vienna, $^4$Center for Anatomy and Cell Biology, Medical University of Vienna, 1090 Vienna, Austria

**9:50 – 10:00 AM**  
**The Anaplastic Large Cell Lymphoma (ALCL)-Associated Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK) Directs Expression of the Nuclear Protein Brahma Related Gene 1 (BRG1) Driving Cell Survival**  
Stephen P. Ducray$^{1,6}$, Gavin D. Garland$^1$, Tu Truong$^1$, Nina Prokoph$^{1,6}$, Kojo S. J.
Elenitoba-Johnson², Megan S. Lim², Olaf Merkel³, Lukas Kenner³, Andrew Bannister⁷ and Suzanne D. Turner¹,⁶

¹Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK CB20QQ, ²Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, ³Medical University of Vienna, Vienna, Austria, ⁴University of Veterinary Medicine Vienna, Vienna, Austria, ⁵Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria, ⁶European Research Initiative for ALK-Related Malignancies (www.erialcl.net), ⁷Gurdon Institute, Cambridge, UK.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 10:15 AM</td>
<td>Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question &amp; Answers</td>
</tr>
<tr>
<td>10:15 – 10:30 AM</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>10:30 – 12:15 PM</td>
<td>PLENARY SESSION VI - T AND NK NON-HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td></td>
<td>Moderators - Ana Xavier, MD, USA &amp; Ritsuro Suzuki, MD, PhD, Japan</td>
</tr>
<tr>
<td>10:30 – 10:50 AM</td>
<td>DIAGNOSIS AND OUTCOME OF EXTRANODAL NK/T-CELL LYMPHOMA IN CHILDREN AND ADOLESCENTS: THE JAPAN EXPERIENCE</td>
</tr>
<tr>
<td></td>
<td>Ritsuro Suzuki, MD, PhD, Japan</td>
</tr>
<tr>
<td>10:50 - 11:10 AM</td>
<td>NOVEL TREATMENT AND OUTCOME OF EXTRANODAL NK AND T-CELL LYMPHOMA: THE BEIJING EXPERIENCE</td>
</tr>
<tr>
<td></td>
<td>Jing Yang, MD, China</td>
</tr>
<tr>
<td>11:10 – 11:30 AM</td>
<td>AUTOLOGOUS VS. ALLOGENEIC HSCT FOR PATIENTS WITH T-CELL AND NK NON-HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td></td>
<td>Amanda Termuhlen, MD, USA</td>
</tr>
<tr>
<td>11:30 – 11:40 AM</td>
<td>Hydroa Vacciniforme–Like Lymphoproliferative Disorder: A Systematic Review</td>
</tr>
<tr>
<td></td>
<td>Liliana Vasquez, M.D.¹; Iván Maza, M.D.¹; Brady Beltrán, M.D.²; María Quiñones, M.D.³</td>
</tr>
<tr>
<td></td>
<td>¹Pediatric Oncology Division, Rebagliati Hospital; Lima, ²Clinical Oncology Department, Rebagliati Hospital; Lima, ³Pathology Department, Rebagliati Hospital; Lima, Peru.</td>
</tr>
<tr>
<td>11:40 – 11:50 AM</td>
<td>Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL)-Rare Non-Hodgkin Lymphoma in Children with Heterogenous Clinical Course. Polish Centres Experience</td>
</tr>
<tr>
<td></td>
<td>Lucyna Maciejka-Kemblowska¹, Marta Kozlowska¹, Jadwiga Maladyk², Marcelina Osak³, Grazyna Wrobel³, Anna Wakulinska⁴, Tomasz Ociep³, Andrzej Koltan⁶, Ewa Dudkiewicz⁷, Ninela Irga-Jaworska³, Bernarda Kazanowska³, Elżbieta Adamkiewicz-Drożyńska¹</td>
</tr>
<tr>
<td></td>
<td>¹Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, ²Department of Developmental Pathology, Medical University of Warsaw, ³Department of Clinic of Pediatric Oncology, Hematology and Bone Marrow Transplantation, Wroclaw Medical University, ⁴Department of Pediatric Oncology, The Children’s Memorial Health Institute, Warsaw, ⁵Department of Pediatrics, Hematology and Oncology, Pomorski Medical University in Szczecin, ⁶Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University, Collegium Medicum Bydgoszcz, ⁷Clinic of Pediatric Hematology and Oncology, Medical University of Lublin, Poland.</td>
</tr>
</tbody>
</table>
Successful Outcome with Reduced-Intensity Condition Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Anaplastic Large-Cell Lymphoma

Reiji Fukano¹², Naoto Fujita³, Tetsuya Mori⁴, Ryoji Kobayashi⁵, Tetsuo Mitsui⁶, Koji Kato⁷, Ritsuro Suzuki⁸, Junji Suzumiya⁹, Takahiro Fukuda⁹, Motohiro Shinoda⁹, Nobuo Maseki¹¹, Tatsu Shimoyama¹², Keiko Okada¹³, Masami Inoue¹⁴, Jiro Inagaki¹, Yoshiko Hashii¹⁵, Atsushi Sato¹⁶, Ken Tabuchi¹⁷

¹Department of Pediatrics, National Kyushu Cancer Center, ²Department of Pediatrics, Yamaguchi University Graduate School of Medicine, ³Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, ⁴Department of pediatrics, St. Marianna University School of Medicine, ⁵Department of Pediatrics, Sapporo Hokuyu Hospital, ⁶Department of Pediatrics, Yamagata University Hospital, ⁷Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, ⁸Department of Oncology/Hematology, Shimane University Hospital, ⁹Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, ¹⁰Division of Gastroenterology and Hematology/Oncology Department of Medicine, Asahikawa Medical University, ¹¹Department of Hematology, Saitama Cancer Center, ¹²Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, ¹³Department of Pediatric Hematology/Oncology, Osaka City General Hospital, ¹⁴Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, ¹⁵Department of Pediatrics, Osaka University Graduate School of Medicine; ¹⁶Hematology and Oncology, Miyagi Children’s Hospital, ¹⁷Division of Pediatrics, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital

Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

LUNCH

PLENARY SESSION VII - NOVEL THERAPEUTICS

Moderators - Veronique Minard-Colin, MD, PhD, France & Matthew Barth, MD, USA

NEW TARGETED THERAPY IN NHL
Mitchell S. Cairo, MD, USA

NOVEL TARGETS AND OUTCOME IN ALCL
Eric Lowe, MD, USA

NOVEL AGENTS IN DEVELOPMENT IN CHILDREN AND ADOLESCENTS WITH HEMATOLOGICAL MALIGNANCIES WITHIN THE EMA
C.M. Zwaan, MD, PhD, Netherlands

Ruxolitinib Significantly Enhances in vitro Apoptosis in Hodgkin Lymphoma (HL) and Primary Mediastinal B-Cell Lymphoma (PMBL) and Survival in a Lymphoma Xenograft Murine Mouse: an AYA Therapeutic Opportunity
Selena R. Levine¹, Tishi Shah¹, Jessica Hochberg¹, Janet Ayello¹, Erin Morris¹, Carmella van de Ven¹ and Mitchell S. Cairo¹,²,³,⁴,⁵
Departments of Pediatrics¹, Cell Biology&Anatomy², Medicine³, Pathology⁴, Microbiology and Immunology⁵, New York Medical College, Valhalla, NY 10595.

2:25 – 2:35 PM  
Ibrutinib Significantly Inhibited Bruton's Tyrosine Kinase (BTK) Phosphorylation, In-Vitro Proliferation and Enhanced Overall Survival in a Preclinical Burkitt Lymphoma (BL) Model
Gaurav Nayyar¹*, Yaya Chu¹*, Tishi Shah¹, Matthew Barth³, Rodney R. Miles⁴, Janet Ayello¹, Erin Morris¹, Lauren Harrison¹, Carmella van de Ven¹, Paul Galardy⁵, Stanton C. Goldman⁶, Megan S. Lim⁷, Michelle Hermiston⁸, Linda M. McAllister-Lucas⁹, Lisa Giulino-Roth¹⁰, Sherrie L. Perkins⁴, and Mitchell S. Cairo¹,¹²,¹¹,¹³
¹Department of Pediatrics, ²Cell Biology & Anatomy, ¹¹Microbiology & Immunology, ¹²Medicine, ¹³Pathology, New York Medical College, Valhalla, NY, Valhalla, ³Pediatrics, University of Buffalo, Buffalo, NY, ⁴Pathology, University of Utah, Salt Lake City, UT, ⁵Pediatrics, Mayo Clinic, Rochester, MN, ⁶Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX, ⁷Pathology and Laboratory Medicine, University of Pennsylvania, PA, ⁸Pediatrics, University of California, San Francisco, CA, ⁹Pediatrics, University of Pittsburgh, Pittsburgh, PA, ¹⁰Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY. *Authors contributed equally to this work.

2:35 – 2:45 PM  
Ompalisib (GSK458), a Dual Pan-PI3K/mTOR Inhibitor, Exhibits in vitro and in vivo Activity in Chemotherapy-Sensitive and –Resistant Models of Burkitt Lymphoma
Thomas Ippolito¹, Greg Tang¹, Cory Mavis², Juan Gu², Francisco Hernandez-Illizaliturri², Matthew J. Barth¹
¹Department of Pediatrics, University at Buffalo, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; ²Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

2:45 – 3:15 PM  
Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

3:15 – 3:30 PM  
COFFEE BREAK

3:30 – 6:00 PM  
PLENARY SESSION VIII - POSTER DISCUSSION SESSION
(ABSTRACTS 1 - 30)
Moderators - Michael Link, MD, USA & Megan Lim, MD, PhD, USA

Staging and Response Evaluation in CAYA NHL –  
Discussant: John T. Sandlund, MD, USA

Can FDG-PET Replace Biopsy for the Evaluation of Residual Tumor in Mature B Cell NHL?
Hany Abdel Rahman, MD ¹, Samah Semary, MD², Gehad Taha, MD³, Naglaa El Kenaalie MD⁴, Iman Zaki MD⁵, Walid Omar MD⁶, Nouran Yasser MSc⁷, Ola Ahmed MSc⁷
¹Department of pediatric oncology National Cancer Institute Cairo University and Children Cancer Hospital, ²Department of Pediatric Oncology, Faculty of Medicine Beni Sweif University and Children Cancer Hospital, ³Department of Surgery, Helwan University and Children Cancer Hospital, ⁴Department of Pathology, National Cancer Institute Cairo University and Children Cancer Hospital, ⁵Department of Radio-diagnosis National Cancer Institute Cairo University, and Children Cancer Hospital, ⁶Department of
Application of the International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLLSS) to Pediatric Patients Newly Diagnosed with B-Cell Non-Hodgkin's Lymphoma (B-NHL) Enrolled in the AIEOP LNH-97 Protocol

Diana Onofrillo, Silvia Pascale, Elisa Carraro, Davide Massano, Lara Mussolin, Rosamaria Mura, Luciana Vinti, Salvatore Buffardi, Piero Farrugia, Simone Cesare, Alessandra Tolva, Patrizia Bertolini, Matilde Piglione, Annalisa Tondo, Nicola Santoro, Alberto Garaventa, Luca Lo Nigro, Alessandra Sala, Marta Pillo

Pediatric Hemato-Oncology Unit, Hematology Dpt, Hospital of Pescara

Clinic of Pediatric Hemato-Oncology, Hospital-University of Padova

Pediatric Hematology Oncology Unit, Hematology Dpt, Hospital of Pescara

Pediatric Hemato-Oncology, Azienda Ospedaliera Universitaria di Pavia

Pediatric Hematology Oncology Unit, Regina Margherita Hospital, University of Torino

Pediatric Hemato-Oncology Dpt, Meyer University-Hospital, Firenze

Division of Pediatric Hematology Oncology, Department of Pediatrics, Bari

Hematology Oncology Unit, G.B. Rossi Hospital, Verona

Pediatric Hematology / Oncology, Fondazione IRCCS Policlinico San Matteo

Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria di Parma

Pediatric Oncology Unit, G.B. Rossi Hospital

Pediatric Hemato-Oncology Unit, Fondazione IRCCS Policlinico San Matteo

Pediatric Oncology Dpt, IRCCS, Bambino-Gesù Children’s Hospital

Pediatric Hemato-Oncology Unit, Pausilipon Company

Department of Paediatric Haematology

Pediatric Hemato-Oncology Unit, San Filippo Hospital, Naples

Department of Paediatric Haemato-Oncology, University of Pisa

Department of Paediatric Haemato-Oncology, University of Padova

Division of Pediatric Hematology Oncology, Department of Pediatrics, Bari

Hematology Oncology Unit, G.B. Rossi Hospital

Pediatric Hematology Oncology Unit, Hematology Dpt, Hospital of Pescara

Division of Pediatric Hematology, Fondazione MBBM, Monza, Italy

Whole-body MRI with Diffusion Weighted Imaging with Body Suppression (DWIBS) in the Follow up of Paediatric Non-Hodgkin Lymphoma: a Comparison with 18F-FDG PET-CT

Tondo A., Olianti C., Azzali A., Cuzzubbo D., Sanfilippo C., Carra F., Favre C., Defilippi C., Perrone AL

Department of Hematology and Oncology, Anna Meyer Children’s University Hospital, Florence

Nuclear Medicine Unit, Careggi University Hospital, Florence

Pediatric Radiology, University of Florence, Anna Meyer Children’s University Hospital, Florence

A Genomic Classification Model Enables Risk Stratification of Paediatric Endemic Burkitt Lymphoma


Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK

College of Medicine, Queen Elizabeth Central Hospital, Department of Paediatrics, Blantyre, Malawi

West Middlesex University Hospital, Department of Histopathology, Isleworth, UK

Imperial College London, Department of Histopathology, London, UK

Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Department of Clinical Research, Children Cancer Hospital, Egypt
Change to OEPA/COPAC and PET-CT Based Treatment Strategy from Former ABVD/COPP for Treating Pediatric Hodgkins Lymphoma - Lessons Learnt from Chandigarh, India
Jaikumar Ramamoorthy, Deepak Bansal, Sonali Mohapatra, Amita Trehan
Pediatric Hematology Oncology Unit, Department of Pediatrics, Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Biology of Anaplastic Large Cell Lymphoma –
Discussant: Megan Lim, MD, PhD, USA

Investigating the Functional Impact of Single Nucleotide Variants in Anaplastic Large Cell Lymphoma
Hugo Larose¹, Shahid Mian², Edem Nuglozeh², Feroze M.S. Fazaludeen³, Ahmed Elmouna², Ibraheem Ashankty², Ming-Qing Du¹, Gerald Hoefler⁴, Sarka Pospisilova⁵, Wilhelm Woessmann⁶, Christine Damm-Welk⁷, Alina Fedorova⁷, Laurence Lamant⁸, Michaela Schlederer⁹, Olaf Merkel⁹, Lukas Kenner⁹,¹⁰,¹¹ and Suzanne D. Turner¹
¹Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK CB20QQ, ²Molecular Diagnostics and Personalised Therapeutics Unit, Colleges of Medicine and Applied Medical Sciences, University of Ha’il, Ha’il, Saudi Arabia, ³Department of Neurobiology, University of Eastern Finland, Finland, ⁴Medical University of Graz, Graz, Austria, ⁵CEITEC, Brno, Czech Republic, ⁶Justus-Liebig University, Giessen, Germany, ⁷Belarusian Centre for Paediatric Oncology, Hematology and Immunology, Minsk, Belarus, ⁸Institut Universitaire du Cancer Toulouse, Oncopole et Université Paul-Sabatier, Toulouse, France, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰University of Veterinary Medicine Vienna, Vienna, Austria, ¹¹Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

Quantification of Minimal Disseminated Disease in Npm-ALK-Positive Anaplastic Large Cell Lymphoma: Validation Cohort and Method
C. Damm-Welk¹, M. Zimmermann¹, A. Attarbaschi², N. Kutscher¹, J. Schieferstein¹, I. Oschlies³, W. Klapper³, W. Woessmann¹
¹NHL-BFM study center, Dept. of Pediatric Hematology and Oncology, Giessen, Germany, ²Dept. of Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Medical University of Vienna, ³Institute of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany

NPM-ALK Expression Levels are Associated to Different miRNA Profiles in Paediatric Anaplastic Large Cell Lymphoma
Anna Garbin¹,², Federica Lovisa¹,², Katia Basso³, Antony B. Holmes³, Elisa Carraro¹, Marco Pizzi⁴, Alberto Garaventa⁵, Annalisa Tondo⁶, Rossella Mura⁷, Salvatore Buffardi⁸, Giuseppe Basso¹,², Emanuele S.G. D’Amore⁹, Marta Pillon¹, Lara Mussolin¹,²
The AP-1 –BATF and –BATF3 Module: Divergent Roles in Tumour Growth, Invasion and Angiogenesis in Anaplastic Large Cell Lymphoma

Liang HC1,7, Prutsch N1,2, Gurnhofer E1, Timelthaler G2, Eferl R2, Tangermann S3, Horvath J1, Stoiber D6,5, Mathas S6,7, Kenner L1,3,4, Merkel O1,7,*

1Clinical Institute for Pathology, Medical University of Vienna, Vienna, Austria; 2Institute of Cancer Research, Medical University of Vienna, Vienna, Austria; 3Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; 4Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria; 5Institute of Pharmacology, Medical University of Vienna, Vienna, Austria; 6Hematology, Oncology and Tumour Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 7European Research Initiative on ALK-related malignancies (ERIA), Cambridge, UK. * Correspondence: olaf.merkel@meduniwien.ac.at

Large B-Cell Lymphomas with ALK-Rearrangement Display a Different Genetic and Epigenetic Profile than Diffuse Large B-Cell Lymphoma

Wagener R1,6, Schnaudt C1,6, Kleinheinz K2,3, Ammerpohl O.1, Altmüller J6, Thiele H5, Kolarova J.1, Agirre X6, Nürnberg P4, Brousset P7,8, Klapper W9, Laurent C.7, Martin-Subero I10, Prósper F6, Woessmann W11, Xerri L12, Schlesner M4,13, Siebert R1

1Institute of Human Genetics, University Ulm and Ulm University Medical Center, Ulm, Germany, 2German Cancer Research Center DKFZ, Division of Theoretical Bioinformatics, Heidelberg, Germany, 3Institute of Pharmacy and Molecular Biotechnology and Bioquant, University of Heidelberg, Heidelberg, Germany, 4Cologne Center for Genomics, Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany, 5Cologne Center for Genomics, University of Cologne, Cologne, Germany, 6Area de Oncología, Centro de Investigación Médica Aplicada,Ciberonc, Universidad de Navarra, Pamplona, Spain, 7Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse, Toulouse, France, 8Laboratoire d'excellence Labex TOUCAN, Toulouse, France, 9Hematopathology Section, Christian-Albrechts-University, Kiel, Germany, 10Institut D’investigaciones Biomedicas August Pi i Sunyer, Center for Biomedical Diagnosis, Barcelona, Spain, 11Pediatric Hematology and Oncology, Justus-Liebig-University, Gießen, Germany, 12Department of Bio-Pathology, Institut Paoli-Calmettes and Aix-Marseille Univ, Marseille, France, 13German Cancer Research Center DKFZ, Bioinformatics and Omics Data Analytics, Heidelberg, Germany. # shared first-authorship
Bone Marrow and Cell Therapy in Relapsed/Refractory NHL – Discussant:
Wilhelm Woessmann, MD, Germany

Therapy and Outcome of Children and Adolescents with Progressive or Relapsed Lymphoblastic Lymphoma: Updated NHL-BFM Experience
Stephanie Müller¹, Heidrun Herbrüggen¹, Andishe Attarbaschi², Edita Kabickova³, Felix Niggli⁴, Ilseke Oschlies⁵, Wolfram Klapper⁵, Martin Zimmermann⁶, Wilhelm Woessmann⁷
Birgit Burkhardt¹
¹Pediatric Hematology and Oncology, University Hospital Muenster, Germany; ²Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Vienna, Austria; ³Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic; ⁴Pediatric Hematology and Oncology, University Hospital, Zürich, Switzerland, ⁵Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany; ⁶Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany; ⁷Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany

Beneficial Effect of aGVHD on Outcomes After Allogeneic Stem Cell Transplantation for Refractory LBL in Children
Tetsuo Mitsui¹, Naoto Fujita², Yuhki Koga³, Reiji Fukano⁴, Tomoo Osumi⁵, Makiko Mori⁶, Koji Kato⁷, Katsuyoshi Koh⁸, Yuri Okimoto⁹, Masami Inoue⁹, Yoshiko Hashii¹⁰, Atsushi Sato¹¹, Yoshiko Atsuta¹², Junji Suzumiya¹³, Ryoji Kobayashi¹⁴
¹Department of Pediatrics, Yamagata University Hospital, Yamagata, Japan; ²Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan; ³Department of Pediatric Medicine for Hospital Collaboration, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ⁴Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan; ⁵Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan; ⁶Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan; ⁷Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; ⁸Department of Hematology and Oncology, Chiba Children's Hospital, Chiba, Japan; ⁹Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan; ¹⁰Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan; ¹¹Department of Hematology/Oncology, Miyagi Children’s Hospital, Sendai, Japan; ¹²Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; ¹³Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital Cancer Center, Izumo, Japan; ¹⁴Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan

BEAM-Campath Conditioning Prior to Allogenic Stem Cell Transplantation in First Remission in Two Cases of Hepatosplenic T Cell Lymphoma
Lane, J.P.¹, Lau, M.², Barge, D.³, Shenton, G.¹, Skinner, R.¹,⁴, James, B.², Wilkins, S.², Bomken, S.¹,⁴
¹Paediatric Oncology and Haematology, Great North Children’s Hospital, Newcastle upon Tyne, UK; ²Children’s and Adolescent Oncology and Haematology, Leeds General Infirmary, Leeds, UK; ³Deparment of Blood Sciences, Royal Victoria Infirmary, Newcastle upon Tyne, UK; ⁴Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
Dissecting EBV-Specific T-cell Responses after Allogeneic EBV-Specific T-Cell Transfer for CNS PTLD
Britta Maecker-Kolhoff1,2, Rebecca E. Schultze-Florey1,2, Sabine Tischer2,3, Leonie Kuhlmann4, Patrick Hundsdoerfer5, Arend Koch6, Sarina Ravens4, Lilia Goudeva3, Christian Schultze-Florey4,7, Christian Koenecke4,7, Rainer Blasczyk3, Ulrike Koehl2,8, Hans-Gert Heuft3, Immo Prinz4, Britta Eiz-Vesper2,3
1Pedicatric Hematology and Oncology, Hannover Medical School, Hannover, 2Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover, 3Institute for Transfusion Medicine, Hannover Medical School, Hannover, 4Institute of Immunology, Hannover Medical School, Hannover, 5Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Berlin Institute of Health, Department of Pediatric Hematology and Oncology, 6Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Berlin Institute of Health, Department of Neuropathology, 7Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Hannover Medical School, Hannover, 8Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany

2B8T2M, a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of anti-CD20 Antibody Significantly Enhanced Expanded Natural Killer Cells Cytotoxicity against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)
Yaya Chu, PhD1, Nang Kham Su, BS1, Emily K. Jeng2, Sarah Alter, PhD3, Peter R. Rhode, PhD3, Gaurav Nayyar1, Mathew Barth, MD4, Dean A. Lee, MD/PhD5, Hing C. Wong, PhD2, Mitchell S. Cairo MD1,6,7,8,9,10
1Pediatrics, New York Medical College, Valhalla, NY, 2HCW Biologics, Miramar, FL, 3Alter BioScience, Miramar, FL, 4Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY, USA, 5Hem/Onc/BMT, Nationwide Children’s Hospital, Columbus OH, 6Medicine, 7Medicine, 8Pathology, 9Microbiology and Immunology and 10Cell Biology and Anatomy, Maria Fareri Children’s Hospital, New York Medical College, Valhalla, NY

Novel Therapeutics in CAYA B-NHL – Discussant:
Michael Link, MD, USA

Low Level of Cerebrospinal fluid (CSF) Rituximab (RTX) following Intravenous Rituximab in Children, Adolescents and Young Adults (CAYA) with de novo Mature B-cell Non-Hodgkin Lymphoma (B-NHL)
Matthew J. Barth1*, Yaya Chu2*, Stanton C. Goldman3, Jessica Hochberg4, Javier Oesterheld4, Kenneth Heym5, Lauren Harrison2, Harshini Mahanti2, Allyson Flowers2, Jackie Basso2 and Mitchell S. Cairo2,6,7,8,9.
1Roswell Park Cancer Institute, Buffalo, NY; 2Department of Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX and Texas Oncology, PA; 3Department of Pediatric Hematology/Oncology, New York Medical College, Valhalla, NY; 4Levine Children’s Hospital, Charlotte, NC; 5Cook Children’s Medical Center, Texas, 6Medicine, 7Pathology, 8Microbiology and Immunology and 9Cell Biology and Anatomy, Maria Fareri Children’s Hospital, New York Medical College, Valhalla, NY *co-primary first authors
Synergistically Enhanced in-vitro Cytotoxicity and Overall Survival in NSG xenografts against Burkitt Lymphoma (BL) and Primary Mediastinal Large B cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu-anti-CD79b-vc-MMAE, PV) alone or in combination with Obinutuzumab

Aradhana Awasthi, MPH, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Christian Klein, PhD, and Mitchell S. Cairo, MD

Department of Pediatrics, Medicine, Pathology, Microbiology & Immunology, Cell Biology & Anatomy, New York Medical College, Valhalla, NY, Department of Medicine, NY, USA, Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Switzerland

Phase 2 Trial of Obinutuzumab, a Humanized, Glycoengineered Monoclonal CD20 Antibody, in Combination with Ifosfamide, Carboplatin and Etoposide for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Mathew J. Barth*, Jessica Hochberg*, Lauren Harrison, Stanton Goldman, Allyson Flowers, Mitchell S. Cairo

Pediatric Hematology/Oncology, Roswell Park Comprehensive Cancer Center and University at Buffalo, Buffalo, NY; Pediatric Hematology/Oncology, New York Medical College, Valhalla, NY; Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX; Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology and Anatomy, New York Medical College, Valhalla, NY * Co-first authors

Comparing Survival Rates Between Pediatric and Adult Regimens of Treatment for B-Cell Non-Hodgkin Lymphoma in Adolescents and Young Adults

Rios L., Castro D., Vasquez L., Geronimo J.

Pediatric Oncology Unit, Hospital Edgardo Rebagliati Martins, Medical Oncology Service, Hospital Edgardo Rebagliati Martins, Lima Peru

Outcomes of Burkitt Lymphomas in Children with a Risk-Stratified Approach at a Tertiary Cancer Center in India

Gaurav Narula*, Anand KC, Maya Prasad, Sneha Shah, Shripad D Banavali

Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India

Molecular Profiling of Adolescent Hepatosplenic T-cell Lymphoma Reveals Somatic Mutations in EZH2, KRAS, and STAG2

Troy A. McEachron, Leonard S. Sender, Keri B. Zabokrtsky, Aaron F. Sassoon, David W. Craig, John D. Carpten, Van T. Huynh, Zarko Manojlovic, Ivan I. Kirov

Keck School of Medicine, University of Southern California, Los Angeles, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, Children’s Hospital of Orange County, Orange, NantKwest, Culver City, University of California Irvine, Orange, California, United States of America
Peripheral T Cell Lymphoma in Children with Nijmegen Breakage Syndrome (NBS) Report of 4 Cases
B. Dembowska-Baginska, A. Wakulinska, M. Stypinska, W. Grajkowska, K. Chrzanowska
Department of Oncology, Department of Pathology, Department of Genetics, The Children’s Memorial Health Institute, Warsaw, Poland

Recurrently Mutated Pathway-Derived Network in Pediatric-Type Follicular Lymphoma
Federica Lovisa, Andrea Binatti, Alessandro Coppe, Simona Primerano, Elisa Carraro, Marta Pillon, Marco Pizzi, Salvatore Buffardi, Fulvio Porta, Piero Faruggia, Raffaella De Santis, Giuseppe Basso, Emanuele SG D’Amore, Stefania Bortoluzzi & Lara Mussolin
1 Clinic of Pediatric Oncology, Department of Women’s and Children’s Health, University of Padova, 2 Istituto di Ricerca Pediatrica Città della Speranza, Padova, 3 Department of Molecular Medicine, University of Padova, Padova, 4 Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padova, 5 Santobono-Pausilipon Hospital, Napoli, 6 Children’s Hospital, Spedali Civili, Brescia, 7 A.R.N.A.S. Ospedali Civico Di Cristina e Benfratelli, Palermo, 8 IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, 9 Department of Pathological Anatomy, San Borotto Hospital, Vicenza, Italy

Investigation of FOXO1 Mutations in Paediatric Endemic and Sporadic Burkitt Lymphoma
Peixun Zhou, Alexander M Newman, Filbert Adlar, Casey Broadbent, Alex E Blain, Amber Whitehead, Amy Hall, George Chagaluka, Elizabeth Molyneux, Simon Bailey, Chris M Bacon, Simon Bomken, Vikki Rand
1 Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK, 2 College of Medicine, Queen Elizabeth Central Hospital Department of Paediatrics, Blantyre, Malawi, 3 Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, 4 Department of Paediatric and Adolescent Haematology and Oncology, The Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Targeted Panel for Pediatric T-LBL
Charlotte Rüther, Tasneem Khanam, Christoph Bartenhagen, Jochen Seggewi, Heidi Herbrüggen, Stephanie Müller, Christian Wünsch, Ilske Oschlies, Wolfram Klapper, Martin Dugas, Sarah Sandmann, Birgit Burkhardt
1 Pediatric Hematology and Oncology, University Hospital Muenster, 2 Department of Experimental Pediatric Oncology, University Hospital Cologne, 3 Institute of Human Genetics, Muenster University, 4 Institute of Medical Informatics, Muenster University, 5 Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany
International CAYA Non-Hodgkin Lymphoma – Discussant: Thomas Gross, MD, USA

Retrospective Analysis of Clinical Features and Treatment Outcomes of Children with Anaplastic Large Cell Lymphoma: A Single Institutional Experience
1Mahreen A, 2Wali RM.
2Department of Pediatric Oncology. Shaukat Khanum Cancer Hospital and Research Center, Lahore, Pakistan

Clinical Features and Outcomes of Pediatric Hodgkin Lymphoma in Asia
Michi Kamei1, Yuhki Koga2, Shih-Hsiang Chen3, Chao-Ping Yang3, Allen Eng Juh Yeoh4, Hany Ariffin5, Reiji Fukano6, Masahiro Sekimizu7, Shosuke Sunami8, Junichi Ueyama9, Tetsuo Mitsui10, Takeshi Mori11, Tomoo Osumi12, Kentaro Ohki13, Fumiko Tanaka14, Naoto Fujita15, Tetsuya Mori16, Ryoji Kobayashi17
1Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Japan, 2Department of Pediatrics, Graduate School of Medical Sciences Kyushu University, Japan, 3Division of Hematology/Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Taiwan, 4National University Cancer Institute Singapore, Singapore, 5Department of Paediatrics University of Malaya Medical Centre, Malaysia, 6Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Japan, 7Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Japan, 8Department of Pediatrics, Japanese Red Cross Narita Hospital, Japan, 9Department of Pediatrics, Tottori University Hospital, Japan, 10Department of Pediatrics, Yamagata University Hospital, Japan, 11Children's Cancer Center, National Center for Child Health and Development, Japan, 12Children's Cancer Center, National Center for Child Health and Development, Japan, 13Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Japan, 14Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital, Japan, 15Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Japan, 16Department of Pediatrics, St. Marianna University School of Medicine Hospital, Japan, 17Department of Pediatrics and Adolescence, Sapporo Hokuyu Hospital, Japan

The Clinical Features and Therapeutic Effect for the Treatment of T cell Lymphoblastic Lymphoma / Leukemia in Childhood and Adolescence: Results of a Single Center in China
1Ling Jin, 1Yonghong Zhang, 1Jing Yang, 1Yanlong Duan, 1Shuang Huang, 1Meng Zhang, 1Chunjv Zhou, 2Zifen Gao, 3Xiaoge Zhou
1Hematology Oncology Center, Beijing Children’ Hospital, Capital Medical University, Beijing, 2Pathology, Medical School of Beijing University, Beijing, 3Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Protocol B-NHL-BFM 95+-/ Rituximab: 10-year Experience
T.Valiev, G.Mentkevich
Pediatric Oncology and Hematology Research Institute of N.N.Blokhin National Cancer Center of the Ministry of Health of Russian Federation, Moscow, Russia
Children are 6 times More Likely than Adults to Develop Post-Transplant Lymphoproliferative Disease (PTLD)

1James Ford, DO, 1Jennifer Sanmann, PhD, 2Kelly Erickson, MPH, 1Martin Bast, 1Wendy Grant, MD, 1Valerie Shostrum, MS, 1Alan Langnas, DO, 1Timothy Greiner, MD, 1Peter Coccia, MD.

1University of Nebraska Medical Center, Omaha, Nebraska, USA, 2Children’s Hospital and Medical Center of Omaha, Omaha, Nebraska, USA

Saturday, September 29, 2018

7:00 AM – 1:00 PM REGISTRATION

7:30 – 8:15 AM MEET THE PROFESSORS (CHOOSE ONE SESSION)

Session 1 MINIMAL DISSEMINATED DISEASE (MDD) AND MINIMAL RESIDUAL DISEASE (MRD) IN CHILDHOOD AND ADOLESCENT NHL
Bruce Shiramizu, MD, USA

Session 2 DIAGNOSIS AND TREATMENT OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE: CHALLENGING CASES
Thomas Gross, MD, PhD, USA

Session 3 DIAGNOSIS AND MANAGEMENT OF LYMPHOBLASTIC LYMPHOMA: CHALLENGING CASES
Birgit Burkhardt, MD, PhD, Germany

Session 4 DIAGNOSIS AND MANAGEMENT OF ALCL: CHALLENGING CASES
Laurence Brugieres, MD, France

Session 5 DIAGNOSIS AND MANAGEMENT OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA: CHALLENGING CASES
Lisa Giulino-Roth, MD, USA

8:30 – 10:00 AM PLENARY SESSION IX - BEST ORAL ABSTRACTS IN CHILDHOOD, ADOLESCENT AND YOUNG ADULT NON-HODGKIN LYMPHOMA
Moderators - Mitchell S. Cairo, MD, USA, & Auke Beishuizen, MD, PhD, Netherlands

8:30 – 8:45 AM Regulation of Cytokine Release and anti-Tumor Effect of anti-CD20 CAR Modified Expanded Natural Killer Cells by ALT-803, an IL-15 Superagonist
Yaya Chu, PhD1, Nang Kham Su, BS1, Carl Hamby, PhD2, Emily K. Jeng3, Sarah Alter, PhD4, Mathew Barth, MD5, Hing C. Wong, PhD3, Dean A. Lee, MD/PhD6, Mitchell S. Cairo MD 1,7,8,9,10,11

1Pediatrics, New York Medical College, Valhalla, NY, 2Microbiology and Immunology, New York Medical College, Valhalla, NY, USA, 3HCW Biologics, Miramar, FL, 4Altor BioScience, Miramar, FL, 5Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY, USA, 6Hem/Onc/BMT, Nationwide Children’s Hospital, Columbus OH, 7Medicine, 8Medicine, 9Pathology, 10Microbiology and Immunology and 11Cell
8:45 – 9:00 AM

**IG-MYC-Rearranged Neoplasms with Precursor B-Cell Immunophenotype in Pediatric and Adolescent Patients**

Heidi Herbrueggen¹, Jonas Rohde², Anja Moericke³, Andishe Attarbaschi⁴, Richard Ratei⁵, Monika Brueggemann⁶, Reiner Siebert⁷, Brigitte Schlegelberger⁸, Wolfram Klappler⁹, Martin Zimmermann¹⁰, Willi Woessmann¹¹, Birgit Burkhardt¹

¹Pediatric Hematology and Oncology, University Hospital Muenster, Germany; ²General Pediatrics, University Hospital Muenster, Germany; ³Department of Pediatrics, University Medical Center Schleswig-Holstein, Kiel, Germany; ⁴Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Medical University of Vienna, Vienna, Austria; ⁵Helios Klinikum Bad Saarow, Department of Hematology, Oncology and Palliative Care, Bad Saarow, Germany; ⁶Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; ⁷Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany; ⁸Department of Human Genetics, Hannover Medical School, Hannover, Germany; ⁹Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany; ¹⁰Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany; ¹¹Pediatric Hematology and Oncology, Justus Liebig University, Giessen, Germany

9:00 – 9:15 AM

**Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma**

Jessica C. Hochberg, MD¹, Liana Klejmont, Pharm D¹, Lauren Harrison, RN, MSN¹, Allyson M. Flower, MD¹, Quihu Shi, PhD², Jaclyn Basso, RN, MSN, PNP¹ and Mitchell S. Cairo, MD¹,³,⁴,⁵,⁶

¹Pediatrics, New York Medical College, Valhalla, NY; ²Statistics, New York Medical College, Valhalla, NY; ³Medicine, ⁴Pathology, ⁵Microbiology and Immunology, ⁶Cell Biology and Anatomy, New York Medical College, Valhalla, NY

9:15 – 9:30 AM

**NPM-ALK REGULATES IMMUNE ESCAPE THROUGH CD48 IN ALK+ ALCLS**

Rui Wu¹, Elena Ivan¹, Delphine Rolland¹, Anagah Sahasrabuddhe¹, Kojo S. Elenitoba-Johnson¹, Megan S. Lim¹,²

¹Department of Pathology and Laboratory Medicine, University of Pennsylvania, PA; ²Department of Pathology, Children’s Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania

9:30 – 9:45 AM

**Biallelic Inactivation of TP53 is Associated with an Increased Risk of Relapse in Paediatric B-Cell Non-Hodgkin Lymphoma (B-NHL)**

Alexander M Newman¹, Masood Zaka¹, Peixun Zhou¹, Amy Erhorn¹, Amy Barnard¹, Rachel E Crossland¹, Sarah Wilkinson¹, Amir Enshaei¹, Mary Taj², Katrina Wood³, Despina Televantou³, Suzanne D Turner⁴, Amos Burke⁵, Christine J Harrison¹, Simon Bomken¹,⁶, Chris M Bacon¹,³, Vikki Rand¹

¹Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle upon Tyne, UK; ²Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Surrey, UK; ³Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; ⁴Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK; ⁵Department of Paediatric Haematology, Addenbrooke’s Hospital, Cambridge, UK
9:45 – 10:00 AM  
Interim Positron Emission Tomography And Childhood Hodgkin International Prognostic Score Can Predict Survival Of Children With Hodgkin Lymphoma In Developing Countries 
Reham Khedr¹, Sally Mahfouz¹, Hoda Fathy², Lobna Shalaby³ 
¹Pediatric Oncology Department, ²Nuclear Medicine Department, National Cancer Institute - Cairo University, Children Cancer Hospital, Egypt, 57357

10:00 – 10:15 AM  
COFFEE BREAK

10:15 - 11:45 AM  
PLENARY SESSION X - LYMPHOBLASTIC LYMPHOMA 
Moderators - Birgit Burkhardt, MD, PhD, Germany & Michelle Hermiston, MD, PhD, USA

10:15 – 10:35 AM  
PROGNOSTIC GENETIC FACTORS IN CHILDHOOD AND ADOLESCENT T-LYMPHOBLASTIC LYMPHOMA 
Birgit Burkhardt, MD, PhD, Germany

10:35 – 10:55 AM  
DIAGNOSIS AND TREATMENT OF CHILDHOOD AND ADOLESCENT B-LYMPHOBLASTIC LYMPHOMA 
Birte Wistinghausen, MD, USA

10:55 – 11:05 AM  
Genomic Analysis of Early T-Cell Precursor Lymphoblastic Lymphoma 
Xinjie Xu¹², Christian N Paxton¹, Robert J. Hayashi³, Sherrie L Perkins¹², Rodney R. Miles¹² 
¹²ARUP Laboratories, Salt Lake City, Utah, ²Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, ³Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, USA

11:05 – 11:15 AM  
Glucocorticoids Paradoxically Induce Steroid Resistance Through a STATS-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia/Lymphoma 
Lauren K. Meyer¹, Cristina Delgado-Martin², Benjamin J. Huang¹, Anica M. Wandler¹, Terzah M. Horton², David T. Teachey³, Kevin M. Shannon¹*, and Michelle L. Hermiston¹* 
¹University of California, San Francisco, CA, ²Baylor College of Medicine, Houston, TX, ³University of Pennsylvania, Philadelphia, PA, USA  *K.M.S. and M.L.H. contributed equally to this study

11:15 – 11:25 AM  
Global Genetic Profiling of a Pediatric Series of T-Cell Lymphoblastic Lymphoma 
¹Idoia Martin-Guerrero*, ²Joan Enric Ramis-Zaldivar*, ³Verónica Cels, ⁴Olga Balagué, ⁵Jaime Verdú, Julia Salmerón-Villalobos, Constantino Sábado, ⁶Marta Garrido, ⁷Blanca Gonzalez-Farré, ⁸Itziar Astigarraga, ⁹Mara Andrés, ¹⁰Itziar Salaverria * These two authors contribute equally to the study 
¹Faculty of Science and Technology, UPV/EHU, Leioa, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ³Hospital Sant Joan de Déu, Esplugues de Llobregat, ⁴Hospital Clínic, Barcelona, ⁵Hospital Clínic, Valencia, ⁶Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ⁷Hospital Vall d’Hebron, Barcelona, ⁸Hospital
Panel Discussion (moderators, plenary speakers, abstract speakers, audience) and Question & Answers

AWARDS SESSION BEST ORAL ABSTRACT, BEST POSTER DISCUSSION ABSTRACT & BEST POSTER ABSTRACT
Award Committee - Marta Pillon, MD, Italy; John T. Sandlund MD, USA; Ronit Elhasid, MD, Israel; Oussama Abla, MD, Canada; Friederike Meyer-Wentrup, MD, Netherlands

CLOSING REMARKS
Mitchell S. Cairo, MD, Chair, USA
ABSTRACT SUBMISSION—DEADLINE May 7, 2018 by 5pm EST

a. ABSTRACTS MUST BE RECEIVED BY Monday, May 7, 2018, 5:00 PM EST, TO BE CONSIDERED FOR PRESENTATION.

b. ABSTRACTS MUST ADDRESS SCIENTIFIC QUESTIONS PERTAINING TO CHILDHOOD, ADOLESCENT, OR YOUNG ADULT NON-HODGKIN LYMPHOMA or HODGKIN LYMPHOMA

c. ABSTRACTS WILL BE PUBLISHED IN BRITISH JOURNAL OF HAEMATOLOGY

d. ABSTRACTS ARE TO BE SUBMITTED VIA E-MAIL AS A MICROSOFT WORD DOCUMENT ATTACHMENT TO NHL_SYMPOSIUM@NYMC.EDU.

e. TO PRESENT AN ABSTRACT, APPLICANT MUST BE REGISTERED TO ATTEND THE SYMPOSIUM

f. THERE IS NO ABSTRACT SUBMISSION FEE

g. YOU CAN REGISTER FOR THE SYMPOSIUM AT THE SAME TIME OF ABSTRACT SUBMISSION AT OUR WEBSITE (http://cayanhl.pcrf-kids.org)

FINANCIAL NEED AWARDS

a. FINANCIAL NEED AWARD --REGISTRANTS FROM A LOW-RESOURCED COUNTRY WHO HAVE AN ABSTRACT ACCEPTED MAY APPLY FOR A MERIT AWARD (REGISTRATION FEE WAIVER). A LETTER BY E-MAIL DETAILING REASONS FOR FINANCIAL NEED MUST BE ATTACHED WITH THE ABSTRACT SUBMISSION. (LIMIT--10 FINANCIAL NEED AWARDS).

BEST ABSTRACT AWARDS

a. BEST ORAL ABSTRACTS WILL BE SELECTED BY SCIENTIFIC MERIT FOR ORAL PRESENTATION IN EACH PLENARY SESSION OF THE MEETING. AN AWARD OF $1000 (US) WILL BE MADE FOR THE BEST ORAL PRESENTATION AT THE MEETING.

b. EIGHTEEN ABSTRACTS OF NOTEWORTHY SCIENTIFIC MERIT WILL BE SELECTED FOR A POSTER DISCUSSION SESSION AT THE MEETING. AN AWARD OF $1000 (US) WILL BE MADE FOR THE BEST POSTER DISCUSSION PRESENTATION AT THE MEETING.

c. ADDITIONALLY, OTHER ACCEPTED ABSTRACTS WILL BE PRESENTED IN THE GENERAL POSTER SESSION. AN AWARD OF $1000 (US) WILL BE MADE FOR THE BEST POSTER IN THE GENERAL SESSION AT THE MEETING.

ABSTRACT FORMAT

a. ABSTRACTS MUST BE SUBMITTED VIA E-MAIL AS A MICROSOFT WORD DOCUMENT ATTACHMENT;

   ABSTRACT SHOULD NOT EXCEED 400 WORDS INCLUDING TITLE AND BODY (AUTHORS' NAMES AND INSTITUTIONS ARE NOT COUNTED). (Limit to one figure or one table are also not counted).

b. USE 10 PT. TIMES FONT.

c. ABSTRACT FORMAT IS AS FOLLOWS:

   TITLE (TITLE CASE)
   AUTHORS, INSTITUTION, CITY, STATE OR PROVINCE, COUNTRY
   BODY (USE THE FOLLOWING HEADINGS):
   BACKGROUND
   OBJECTIVES
   DESIGN/METHODS
   RESULTS
   CONCLUSION

THE FOLLOWING INFORMATION MUST BE INCLUDED IN THE E-MAIL WITH EACH SUBMISSION:

a. NAME OF CORRESPONDING AUTHOR
b. DEPARTMENT/INSTITUTION, CITY, COUNTRY
c. TELEPHONE NUMBER
d. E-MAIL ADDRESS OF CORRESPONDING AUTHOR
e. CATEGORY DESIRED (AUTHORS MUST INDICATE THE ONE SCIENTIFIC CATEGORY)

<table>
<thead>
<tr>
<th>1.</th>
<th>B-CELL NON-HODGKIN LYMPHOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.</td>
<td>AYA NON-HODGKIN AND HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td>3.</td>
<td>T AND NK NON-HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td>4.</td>
<td>LYMPHOMA IMMUNOLOGY, BMT &amp; CELL THERAPY</td>
</tr>
<tr>
<td>5.</td>
<td>ANAPLASTIC LARGE CELL LYMPHOMA</td>
</tr>
<tr>
<td>6.</td>
<td>LYMPHOMA TRANSLATIONAL BIOLOGY</td>
</tr>
<tr>
<td>7.</td>
<td>NOVEL THERAPEUTICS</td>
</tr>
<tr>
<td>8.</td>
<td>LYMPHOBLASTIC LYMPHOMA</td>
</tr>
<tr>
<td>9.</td>
<td>RELAPSED/REFRACTORY NHL</td>
</tr>
<tr>
<td>10.</td>
<td>LATE EFFECTS / SURVIVORSHIP OF NHL</td>
</tr>
<tr>
<td>11.</td>
<td>HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td>12.</td>
<td>NHL IN LOW RESOURCED COUNTRIES</td>
</tr>
</tbody>
</table>

• ABSTRACTS PERTINENT TO CHILDHOOD, ADOLESCENT AND YOUNG ADULT NON-HODGKIN AND HODGKIN LYMPHOMA THAT HAVE BEEN ACCEPTED/PRESENTED AT SCIENTIFIC MEETINGS WITHIN THE PAST 18 MONTHS ARE ALSO ACCEPTABLE FOR SUBMISSION TO THIS SYMPOSIUM.

• QUESTIONS SHOULD BE ADDRESSED TO MIGUEL MUNIZ AT NHL_SYMPOSIUM@NYMC.EDU

• SUBMIT ABSTRACT BY E-MAIL TO:  NHL_SYMPOSIUM@NYMC.EDU

• ABSTRACT REVIEW:

a. ABSTRACTS WILL BE PEER-REVIEWED ACCORDING TO SCIENTIFIC CATEGORIES.

b. NOTIFICATION OF ACCEPTANCE OR REJECTION OF ABSTRACTS WILL BE MADE VIA E-MAIL ON OR AROUND June 11th, 2018.

c. THE DECISION OF THE REVIEWING COMMITTEES REGARDING THE ACCEPTANCE OF ABSTRACTS IS FINAL.
CME Information
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of New York Medical College and Pediatric Cancer Research Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this Live activity for a maximum of 24.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LOCATION: ROTTERDAM, THE NETHERLANDS
Rotterdam, a city known for its architecture, is a Dutch city situated in the west part of The Netherlands. A major logistic and economic center, Rotterdam is Europe’s largest port city with a population of 633,000 and over 2.9 million inhabitants in its metropolitan area combined with The Hague. Rotterdam is a modern, thriving cosmopolitan city with a breathtaking skyline and a wealth of cultures and ethnicities.

VENUE: DE DOELEN INTERNATIONAL CONGRESS CENTRE
The Willem Burger Complex
De Doelen ICC is Rotterdam’s central arena for the exchange of information and cultural events. De Doelen ICC is divided into 3 complexes each with its own entrance. De Doelen ICC has earned a national and international reputation for its state of the art venue. The 6th International Symposium is being held in the Willem Burger Complex.

REACHING ROTTERDAM:
Symposium attendees can reach Rotterdam by air and train. Amsterdam’s Schiphol Airport (AMS) is located 37 miles north of Rotterdam. From Schiphol Airport travel to Rotterdam City Center Rail Station is by high speed rail service operated by NS Dutch Railways. The high speed train operates from Schiphol Airport to Rotterdam City Center Rail Station every 15 minutes and the journey takes 27 minutes. De Doelen ICC and recommended hotels are within walking distance from Rotterdam City Center Rail Station.

For travelers arriving from Germany, Italy, France, Spain and the United Kingdom flights are available to Rotterdam The Hague Airport (RTM). Rotterdam The Hague Airport is located 4 miles north of the city with taxi service available.

ACCOMMODATIONS/REGISTRATION:
RESERVE ONLINE at http://cayanhl.pcrf-kids.org

A limited number of favorable hotel rates for conference registrants are available at:
The Bilderberg Park Hotel; Easy Hotel Rotterdam City Centre; The Holiday Express Rotterdam; Marriott Rotterdam
All hotels are within walking distance of De Doelen ICC.

Hotel accommodations must be reserved by August 26, 2018 to assure availability of blocked rooms at conference rates.

CONFERENCE REGISTRATION FEES INFORMATION *USD:

<table>
<thead>
<tr>
<th>Registration</th>
<th>By August 15th, 2018</th>
<th>After August 15th, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians / Scientists</td>
<td>$750.00 USD</td>
<td>$900.00 USD</td>
</tr>
<tr>
<td>Allied Professional / In Training</td>
<td>$450.00 USD</td>
<td>$600.00 USD</td>
</tr>
<tr>
<td>Pharmaceutical Representative</td>
<td>$1,000.00 USD</td>
<td>$1,250.00 USD</td>
</tr>
<tr>
<td>CME Credit</td>
<td>$25.00 USD</td>
<td>$25.00 USD</td>
</tr>
</tbody>
</table>

US currency only

REGISTER ONLINE: http://cayanhl.pcrf-kids.org

Refund Policy:
50% of registration is refundable by July 15th, 2018, thereafter there are no refunds.

Late and On-Site Registration (After July 15th, 2018):
Attendees who register after July 15th, 2018 will be charged the late/on-site registration fee. On-site registration will begin on local times list below in the first-floor lobby of the De Doelen International Congress Centre.

Meeting Cancellation Policy:
The Pediatric Cancer Research Foundation (PCRF), New York Medical College and Erasmus MC reserve the right to modify or cancel any or all activities associated with this meeting due to unforeseen circumstances. In the event that we have to unexpectedly cancel this meeting before July 15, 2018, 50% off the registration fee will be returned. If the conference is cancelled after July 15, 2018, there will be no refund.